Nicholas Licari
Family · Florence, SCNPI 1558721779
Payments from drug & device makers
Across 212 payments — averaging $15.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$891
- Novo Nordisk$755
- GSK$288
- Novartis$151
- Bayer$130
- Amgen$128
- plus $973 from 26 others
What the payments were for
- Food & beverage$3,28499%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 56 | $891 |
| Novo Nordisk | 56 | $755 |
| GSK | 18 | $288 |
| Novartis | 9 | $151 |
| Bayer | 8 | $130 |
| Amgen | 8 | $128 |
| Lilly USA, LLC | 8 | $120 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $80 |
| Boehringer Ingelheim | 5 | $80 |
| Dexcom, Inc. | 4 | $73 |
| Stryker | 1 | $60 |
| Xeris Pharmaceuticals, Inc. | 3 | $59 |
| Amarin Pharma, Inc. | 2 | $46 |
| Johnson & Johnson | 3 | $40 |
| Dynavax Technologies Corporation | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 4 | $35 |
| Pfizer | 2 | $33 |
| Abbott | 2 | $33 |
| AstraZeneca | 2 | $31 |
| Merck | 2 | $28 |
| Averitas Pharma Inc. | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Shield Therapeutics Inc | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Eisai Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Verona Pharma, Inc. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Cequr Corporation | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $12 |
How this compares
$3,316 in reported general payments places this provider in the 85th percentile of 3,248 family providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 385 | $425,215 |
| JardianceEmpagliflozin | 206 | $223,091 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 143 | $173,666 |
| MounjaroTirzepatide | 140 | $162,001 |
| LinzessLinaclotide | 106 | $124,220 |
| EliquisApixaban | 84 | $91,876 |
| KerendiaFinerenone | 45 | $54,184 |
| FarxigaDapagliflozin Propanediol | 51 | $49,537 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 37 | $47,086 |
| EntrestoSacubitril/Valsartan | 25 | $40,338 |
| TrulicityDulaglutide | 37 | $38,921 |
| Tresiba Flextouch U-200Insulin Degludec | 50 | $35,230 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 43 | $32,715 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $31,706 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $27,800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $755 | $425,215385 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat, Combivent Respimat, Tradjenta | $80 | $323,728323 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $288 | $234,180221 claims |
| Lilly USA, LLCMounjaro, Trulicity | $120 | $200,922177 claims |
| AbbVieLinzess | $891 | $124,220106 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere, Brilinta, Symbicort | $31 | $104,100119 claims |
| PfizerEliquis | $33 | $91,87684 claims |
| BayerKerendia | $130 | $54,18445 claims |
| NovartisEntresto | $151 | $40,33825 claims |
| MerckJanumet Xr | $28 | $22,82026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,248 family providers in South Carolina.
Other family in Florence
- Sharon WaltersFlorence$19K
- Pansi PatelFlorence$13K
- Elizabeth WoodberryFlorence$10K
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.